SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors debate its massive cash pile and underperformance relative to the broader market, with many pinning their hopes on the upcoming annual meeting for clarity on CEO Greg Abels leadership strategy. Community sentiment is deeply divided between long-term supporters viewing the stock as a defensive value anchor and frustrated traders rotating into higher-growth AI and tech sectors.

Liquid Mercury is a technology company that provides institutional-grade trading infrastructure, workflow automation, and Real World Asset (RWA) marketplaces. Its platform is designed to meet the performance, security, and reporting standards expected by the most demanding traditional finance institutions.  At the core of the ecosystem is MERC, an ERC-20 utility token that delivers value to users in three primary ways:  1. Discount Farming via Staking  MERC holders can participate in a “Discount Farming Staking Program,” which enables users to earn monthly Element Tokens (ETs) by staking their MERC tokens. These ETs can be:  - Applied toward Liquid Mercury invoices for service discounts, if you're a customer. - Traded for cash equivalents on a private secondary marketplace where ET holders and Liquid Mercury customers can buy and sell ETs.  2. Access to Premium Features and Staking Rewards  Staking MERC also unlocks:  - Access to exclusive research, curated trading tools, and trading rebates. - Annual staking rewards paid in MERC, currently set at 10% per year.  3. Utility in the Expansion of Real World Asset (RWA) Markets  As Liquid Mercury grows its footprint in the RWA sector, the role of the MERC token will expand accordingly, powering participation and utility within tokenized asset marketplaces.

Liquid Mercury

Liquid Mercury is gaining traction as community members highlight continuous development updates, including new website features and the TokenBloq integration. Investors are actively tracking the project's institutional-grade infrastructure and its high-profile backing as part of broader ecosystem partnerships.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

$SPERMWHALE is trending as investors actively discuss its potential for rapid price surges, utility features like buybacks, and its status within the volatile meme coin community. The conversation is driven by a mix of speculative enthusiasm for breaking new all-time highs and persistent debate regarding the project's sustainability compared to other emerging tokens.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending after reports surfaced that the company is preparing an offer to acquire eBay, fueling aggressive retail speculation about a potential strategic pivot into e-commerce. While the community is actively debating the feasibility of the merger given the valuation gap, the news has ignited significant options activity and excitement over a potential short squeeze.

Peanut the Squirrel Markets

PNUT is seeing heightened social media activity as traders speculate on its potential for a breakout, driven by the broader meme coin rotation and optimism surrounding crypto market sentiment. The community is actively debating the token's long-term potential compared to other popular memes, while monitoring key support levels and price action for signs of an impending move.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently a focal point for investors due to positive clinical data for its lead oral drug, Soquelitinib, which has fueled speculation regarding potential M&A activity and institutional accumulation. While the community is debating whether the stock is undergoing a healthy consolidation or a speculative pump, discussion remains heavily focused on upcoming clinical milestones and the potential for a major pharmaceutical acquisition.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending due to surging M&A speculation, with renewed reports from French media identifying Eli Lilly and AstraZeneca as potential suitors. The community is focused on the stock's M&A premium and recent positive data readouts, fueling intense interest in a possible high-value acquisition of the company's inflammatory disease platform.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic remains a focal point for the community as investors debate the impact of potential burn mechanisms and the long-term viability of the chain's revival efforts. Discussions are heavily divided between those highlighting bullish technical patterns and opportunistic accumulation strategies, and others dismissing the asset as a speculative pump-and-dump venture.

What is Chronotech? Chrono.tech provides blockchain-based solutions for recruitment, HR and payment processes, reducing the barriers to accessing work and transferring funds securely in the global labor marketplace. The project’s suite of services - and native governance token TIME - are hosted on multiple blockchains and include LaborX.com, a peer-to-peer freelancer marketplace, TimeX.io, a Plasma-based cryptocurrency exchange; AUDT, an Australian dollar-backed stablecoin; and PaymentX, a crypto invoicing and payroll solution.  TIME token The TIME token is the native token of the Chrono.tech ecosystem and can be used within its products, e.g. to secure premium account status, as well as staking TIME on TimeWarp.finance to receive the revenues generated by all services. In November 2020, the original TIME token was upgraded to the new ERC677 standard, enabling it to be integrated with other DeFi protocols, allowing lower-cost transactions, and providing other advantages, while remaining fully ERC20-compatible. The new TIME 2.0 token contract also included up-to-date metadata about the project.  Chrono.tech products and ecosystem Chrono.tech aims to solve a series of problems in the global recruitment and employment markets. LaborX is Chrono.tech’s freelance work portal. The service allows freelancers and customers to organise work via digital agreements, powered by smart contracts. All payments are escrowed and made in cryptocurrency. Once a job is completed, escrowed payments are released automatically. A dispute resolution service is available in case of disagreement. TimeX is Chrono.tech’s cryptocurrency exchange. TimeX is a hybrid Plasma-based exchange that offers the benefits of both centralised and decentralised technologies. Use of Plasma allows for fast, secure trading of digital assets. The conventional interface provides a user-friendly trading experience. Based in Australia, TimeX is licensed and compliant with rules and best practices required by AUSTRAC, the country’s financial intelligence agency. TimeX is listed on CoinMarketCap https://coinmarketcap.com/exchanges/timex/ TimeWarp is the ecosystem’s DeFi yield farming application where TIME holders can stake their token to earn revenues generated by all products of the Chrono.tech product range. All 100% of revenues generated are being distributed to TIME holders on a weekly basis. AUDT is a stablecoin, hosted on the Ethereum blockchain and backed 1:1 with Australian dollars (AUD). Use of AUDT enables traders to move money into and out of the blockchain ecosystem from an Australian bank account, to store value in AUD on the blockchain and transfer funds anywhere in the world, quickly and easily. AUDT is one of the key fiat currencies traded on TimeX. AUDT is fully compliant with AUSTRAC requirements and undergoes regular audits conducted by a licensed, third party accounting firm. PaymentX is a multi-currency crypto payroll solution that enables individuals as well as businesses to integrate crypto payments into their day-to-day invoice processes. Contractors can submit professional invoices and specify a crypto wallet for payment. Companies can pay multiple invoices with one click, while the software converts the dollar-equivalent amount due into crypto automatically at the point of transaction, avoiding the need for manual calculations. TimeBridge is an in-house developed multi-blockchain tokenbridge that supports multiple blockchains such as Ethereum and BSC. It allows transferring of TIME tokens between networks.

Chronobank

Chronobank is currently generating significant social media conversation driven by its extremely low circulating supply and community-led efforts to create scarcity through buybacks and token burns. Investors are actively debating the asset's potential for volatile price swings, with many highlighting its history of rapid spikes and viewing current price levels as a strategic entry point.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as the community closely monitors legislative developments around the Clarity Act, which many believe will solidify the token's status as a digital commodity and drive institutional adoption. While some investors are aggressively accumulating in anticipation of a major run, ongoing debates between banking interests and crypto proponents continue to fuel both optimistic speculation and skepticism regarding the project's long-term utility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Goldman Sachs Lifts UnitedHealth Target Price: Healthcare ETFs to Watch

Goldman lifts UnitedHealth's target price, spotlighting ETFs like IHF as diversified ways to tap its growth while cushioning Medicaid-driven risks.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Consumer Sentiment Weakens: ETFs That Are Worth a Look

Rising oil prices and Middle East tensions are squeezing household finances and weakening consumer sentiment, steering investors toward defensive ETFs.

Stagflation Scare? ETFs May Help Protect Your Portfolio

Are stagflation risks returning as oil-driven inflation rises amid Middle East tensions? Here's how ETFs can help defend portfolios.

Middle East Turmoil and U.S. Debt Surge: ETFs in Focus

With U.S. budget deficits and already elevated debt, the ongoing Middle East war could worsen the fiscal outlook, making defensive ETF strategies worth considering for stability.

<ul class="summary-bullets"><li>Revenue recognized under the Sanofi agreement, including milestone and royalty payments, amounted to $98 million in Q4.</li><li>The company recorded net income of $18 million during the quarter, compared to an $81 million loss during the year-ago period.</li><li>Selling, general, and administrative expenses fell 53% year-over-year.&nbsp;</li></ul>Novavax, Inc. (NVAX) reported a sharp increase in fourth-quarter (Q4) and 2025 revenue as the vaccine maker leaned on partnership income, cost cuts and product sales.The Maryland-based biotech generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11. Both the metrics surpassed the analysts’ consensus estimates of $90.26 million and a loss of $0.55, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Q4 Performance Highlights</h2>Annual revenue surged 65% YoY to $1.12 billion, driven in large part by $625 million in Nuvaxovid sales linked primarily to settlements of earlier advance purchase deals.Quarterly product sales totaled $39 million, while full-year product sales rose to $685 million. Revenue recognized under the Sanofi agreement, including milestone and royalty payments, amounted to $98 million in Q4 and $386 million for the year. The company said it earned $225 million in milestones from the Sanofi collaboration in 2025.<blockquote>"In 2025, we made significant progress on our corporate strategy, marked with the successful achievement of key milestones under our Sanofi agreement, progress towards potential new partnerships, in the form of multiple MTAs signed with other parties enabling experimentation with our Matrix-M adjuvant technology and the advancement of our own R&amp;D efforts.”-John C. Jacobs, President and CEO, Novavax</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/NVAX">Novavax stock</a> traded over 1% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;&nbsp;<h2 class="st-heading-2">Costs Fall As Profitability Improves</h2>Novavax reduced its cost of sales to $22 million in the fourth quarter from $37 million a year earlier. The decline followed the divestiture of its Czech manufacturing site and lower overhead and inventory-related charges.Selling, general, and administrative expenses fell more than half YoY as commercial responsibilities transitioned to Sanofi and infrastructure was streamlined. The company recorded net income of $18 million in Q4, compared to an $81 million loss during the year-ago period. Novavax ended 2025 with $751 million in cash and equivalents.&nbsp;NVAX stock has gained ovr 0% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-falls-premarket-es8-demand-powers-through-chip-shortage/cZTG3ncRIbK">Nio Stock Falls Premarket: Flagship ES8 Demand Powers Through Fresh Chip Shortage Disruption</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue 

The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11.

Equity

<ul class="summary-bullets"><li>PROCEPT BioRobotics’ Q4 revenue of $76.4 million and loss per share of $0.53 both missed street estimates.&nbsp;</li><li>According to Bank of America, in Q4, PROCEPT BioRobotics delivered results that fell short of analyst forecasts by 18.5%.</li><li>The firm indicated that the latest quarterly update failed to ease concerns about execution and financial momentum.</li></ul>Bank of America has downgraded PROCEPT BioRobotics Corp. (PRCT) shares, citing mounting concerns about earnings visibility and profitability, reflecting skepticism about the company’s near-term performance as it navigates widening losses.In the fourth quarter (Q4), the company reported a revenue of $76.4 million, a 12% year-over-year (YoY) increase, and a loss per share (EPS) of $0.53. Both the financial metrics were below the analysts’ consensus estimates of $93.70 million and a loss of $0.31, respectively, according to Fiscal AI data.&nbsp;<a href="https://stocktwits.com/symbol/PRCT">PROCEPT BioRobotics’ stock</a> traded over 28% lower in Thursday’s premarket.&nbsp;<h2 class="st-heading-2">BofA Flags Profitability Concerns</h2>Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’ and slashed its price target to $20 from $38, according to TheFly. The firm flagged fresh doubts following the company’s Q4 earnings discussion, noting uncertainty about whether management can meet Wall Street’s projections.&nbsp;Bank of America indicated that the latest quarterly update failed to ease concerns about execution and financial momentum.According to Bank of America, in Q4, PROCEPT BioRobotics delivered results that fell short of analyst forecasts by 18.5%. The shortfall coincides with a shift in the company’s longstanding approach to offering volume-based discounts to customers. At the same time, management has undertaken a reorganization of its sales team, adding another layer of transition risk.The firm emphasized that the company remains unprofitable, with operating losses deepening after the latest earnings. That trend, Bank of America argued, constrains the stock’s valuation and limits potential upside in the near term.&nbsp;<h2 class="st-heading-2">Retail Traders Remain Bullish Despite Selloff</h2>However, on Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume flipped to ‘extremely high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_26_055954_png_4ab610861f.webp" alt="PRCT’s Sentiment Meter and Message Volume as of 05:30 a.m. ET on Feb. 26, 2026 | Source: Stocktwits" width="933" height="101"><figcaption>PRCT’s Sentiment Meter and Message Volume as of 05:30 a.m. ET on Feb. 26, 2026 | Source: Stocktwits</figcaption></figure>PRCT stock has declined by over 59% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-falls-premarket-es8-demand-powers-through-chip-shortage/cZTG3ncRIbK">Nio Stock Falls Premarket: Flagship ES8 Demand Powers Through Fresh Chip Shortage Disruption</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the PROCEPT BioRobotics Corporation logo is seen displayed on a smartphone screen.

PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20

Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’. 

<ul class="summary-bullets"><li>The reverse split will consolidate every 30 existing shares into one new share.</li><li>The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.</li><li>After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million.</li></ul>Incannex Healthcare Inc. (IXHL) announced on Wednesday that its board of directors has approved a 1-for-30 reverse stock split, which was previously approved by shareholders at a special meeting on May 27, 2025.The reverse split is set to take legal effect at 4:01 p.m. ET on Feb. 26, 2026.<h2 class="st-heading-2">Purpose And Impact Of The Split</h2>Following this adjustment, Incannex Healthcare common shares will begin trading on The Nasdaq Capital Market under a new CUSIP number, 45333F 208, on February 27, while retaining the ticker symbol ‘IXHL’.The reverse split will consolidate every 30 existing shares into one new share, aiming to raise the per-share market price. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements and maintain continued listing eligibility.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/IXHL">Incannex stock</a> tumbled over 32% on Wednesday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Share Structure And Equity Adjustments</h2>Incannex said that&nbsp;no fractional shares will be issued, and shareholders entitled to fractional amounts will receive an additional share to round up to a whole unit.&nbsp;After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million, although the total number of authorized shares will remain unchanged. Existing equity awards and stock incentive plans will see proportional adjustments in both share numbers and exercise prices to reflect the split.&nbsp;In January, Incannex said it is entering 2026 with over $70 million in cash, following a $12.5 million private placement financing and the elimination of legacy Series A warrants. The company also authorized a $20 million share repurchase program.IXHL stock has declined by over 87% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q4-earnings-today-retail-says-pressure-is-worse-this-time/cZRy3JBRIG4">Nvidia Q4 Earnings Today – Retail Says 'Pressure Is Worse This Time’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background.

Why Did IXHL Stock Tank Over 32% Today? 

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. 


<ul class="summary-bullets"><li>Geron posted RYTELO net product sales of $48 million in the fourth quarter, and the number of ordering accounts increased to roughly 1,300.</li><li>In December, Geron initiated a workforce reduction affecting about one-third of employees, resulting in $17 million in restructuring charges.</li><li>For 2026, Geron projects RYTELO revenue between $220 million and $240 million.</li></ul>Geron Corp. (GERN) reported fourth-quarter and full-year 2025 results on Wednesday, highlighting rising sales of its blood cancer therapy RYTELO as the company sharpens its focus on expanding adoption in lower-risk myelodysplastic syndromes (LR-MDS).Total revenue reached $48 million in the fourth quarter, with a loss per share (EPS) of $0.05. Both the metrics&nbsp;came&nbsp;in below the analysts’ consensus estimates of $50.88 million and a loss of $0.04, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">RYTELO Sales And Demand Climb</h2>However, Geron posted RYTELO net product sales of $48 million for Q4 and $183.6 million for the full year. Demand rose 9% in the fourth quarter compared with the prior quarter, while the number of ordering accounts increased by 150 to roughly 1,300.The company said it is supporting more than 10 investigator-sponsored and real-world studies examining RYTELO’s mechanism, potential combinations, and earlier-line use. Initial findings from those efforts are anticipated in the second half of 2026.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/GERN">Geron's stock</a> traded over 10% lower in Wednesday’s premarket. However, on Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Expenses And Outlook&nbsp;</h2>Operating costs for 2025 were $254.7 million. Research and development spending declined, reflecting reduced clinical trial activity after the FDA’s RYTELO approval in 2024. Selling, general, and administrative costs increased due to expanded commercial efforts. In December, Geron initiated a workforce reduction affecting about one-third of employees, resulting in $17 million in restructuring charges.For 2026, Geron projects RYTELO revenue of $220 million to $240 million, with operating expenses of $230 million to $240 million.GERN stock declined by over 17% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rbbn-stock-gains-pre-market-today-what-is-behind-the-rally/cZRyd8HRIGE">RBBN Stock Gains Over 8% Pre-Market Today – What’s Behind The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Why Did GERN Stock Tumble 10% Pre-Market Today? 

Total revenue reached $48 million for the fourth quarter, with a loss per share of $0.05, with both metrics coming in below street estimates. 

<ul class="summary-bullets"><li>The therapy is to treat adults and children with Friedreich’s ataxia, a progressive neurodegenerative disorder.</li><li>Preliminary findings from the open-label study show that nomlabofusp increased FXN levels in patients’ skin to amounts observed in asymptomatic carriers.&nbsp;</li><li>FDA agreed that skin FXN could serve as a novel surrogate endpoint, supporting the planned Biologics License Application submission.</li></ul>Larimar Therapeutics, Inc. (LRMR) announced on Tuesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its frataxin (FXN) protein replacement therapy, nomlabofusp.&nbsp;The therapy is to treat adults and children with Friedreich’s ataxia (FA), a progressive neurodegenerative disorder causing nervous system damage.<h2 class="st-heading-2">FDA Endorses Skin FXN As Surrogate Endpoint</h2>The FDA’s decision follows encouraging clinical data from Larimar’s ongoing open-label study and a recent Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program meeting.&nbsp;The agency also agreed that skin FXN could serve as a novel surrogate endpoint reasonably likely to predict clinical benefit, supporting the planned Biologics License Application (BLA) submission targeted for June 2026. The FDA additionally confirmed that the planned analyses, reference population, and clinical endpoints are aligned with BLA requirements.Following the FDA’s decision,&nbsp;<a href="https://stocktwits.com/symbol/LRMR">Larimar stock</a> traded over 30% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_24_084542_png_18caaedccf.webp" alt="LRMR’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits" width="932" height="105"><figcaption>LRMR’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Encouraging Clinical Data</h2>Preliminary findings from the open-label study show that nomlabofusp increased FXN levels in patients’ skin to amounts observed in asymptomatic carriers.&nbsp;Improvements were seen across four key clinical measures, the modified Friedreich Ataxia Rating Scale (mFARS), FARS-Activities of Daily Living (ADL), 9-Hole Peg Test (9-HPT), and Modified Fatigue Impact Scale (MFIS) after one year of treatment.&nbsp;The results suggest that nomlabofusp could slow or reverse FA progression compared with the natural disease course observed in the Friedrich’s Ataxia Clinical Outcomes Measure Study (FACOMS).LRMR stock declined by over 7% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intuit-stock-rallies-pre-market-today-anthropic-connection/cZRvyjtR4C7">Intuit Stock Rallies Pre-Market Today And There’s An Anthropic Connection</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? 

The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp.

IYH
iShares US Healthcare ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IYH News

IYHiShares US Healthcare ETF